The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Evaluating first-line therapies for EGFR-mutated NSCLC in 2024
Shirish Gadgeel, MD, Henry Ford Cancer Institute/Henry Ford Health, Detroit, MI, compares and contrasts existing first-line therapies for EGFR-mutated non-small cell lung cancer (NSCLC). The Phase III MARIPOSA study (NCT04487080) has resulted in another option for clinicians, and patient features should be taken into consideration when choosing the best therapy. However, more research is needed to further refine patient selection. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
